Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2024. CEO Natalie Holles will engage in fireside chats at the following events:
- Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET
- TD Cowen Virtual Chronic Urticaria Summit on September 20, 2024, at 3:00 p.m. ET
The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these sessions on its website. Archived replays will be available for 90 days after the events.
Third Harmonic Bio (Nasdaq: THRD), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a due prossimi convegni per investitori nel settembre 2024. L'amministratore delegato Natalie Holles parteciperà a conversazioni informali nei seguenti eventi:
- Il Summit virtuale su Immunologia e Infiammatori della Stifel 2024 il 18 settembre 2024, alle 9:00 ET
- Il Summit virtuale su Urticaria Cronica della TD Cowen il 20 settembre 2024, alle 15:00 ET
L'azienda, che si concentra sullo sviluppo di trattamenti innovativi per le malattie infiammatorie dermiche, respiratorie e gastrointestinali, fornirà webcast audio dal vivo di queste sessioni sul proprio sito web. Le registrazioni archiviate saranno disponibili per 90 giorni dopo gli eventi.
Third Harmonic Bio (Nasdaq: THRD), una empresa biofarmacéutica en fase clínica, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024. La CEO Natalie Holles participará en charlas informales en los siguientes eventos:
- La Cumbre Virtual de Inmunología e Inflamaciones de Stifel 2024 el 18 de septiembre de 2024, a las 9:00 a.m. ET
- La Cumbre Virtual de Urticaria Crónica de TD Cowen el 20 de septiembre de 2024, a las 3:00 p.m. ET
La empresa, que se centra en desarrollar tratamientos innovadores para enfermedades inflamatorias dérmicas, respiratorias y gastrointestinales, proporcionará transmisiones de audio en vivo de estas sesiones en su sitio web. Las repeticiones archivadas estarán disponibles durante 90 días después de los eventos.
Third Harmonic Bio (Nasdaq: THRD)는 임상 단계의 생명공학 회사로서 2024년 9월에 열리는 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다. CEO Natalie Holles는 다음 이벤트에서 대화에 참여할 예정입니다:
- 2024년 9월 18일 오전 9시(ET)에 열리는 Stifel 가상 면역학 및 염증 정상 회담
- 2024년 9월 20일 오후 3시(ET)에 열리는 TD Cowen 가상 만성 두드러기 정상 회담
해당 회사는 피부, 호흡기 및 위장관 염증성 질환에 대한 혁신적인 치료제를 개발하는 데 주력하고 있으며, 이러한 세션의 실시간 오디오 웹캐스트를 자사 웹사이트에서 제공할 예정입니다. 이벤트 후에는 90일 동안 아카이브된 재생을 이용할 수 있습니다.
Third Harmonic Bio (Nasdaq: THRD), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. La PDG Natalie Holles participera à des discussions informelles lors des événements suivants :
- Sommet virtuel sur l'immunologie et l'inflammation de Stifel 2024 le 18 septembre 2024 à 9h00 ET
- Sommet virtuel sur l'urticaire chronique de TD Cowen le 20 septembre 2024 à 15h00 ET
L'entreprise, qui se concentre sur le développement de traitements innovants pour des maladies inflammatoires dermiques, respiratoires et gastro-intestinales, fournira des webcasts audio en direct de ces sessions sur son site web. Les rediffusions archivées seront disponibles pendant 90 jours après les événements.
Third Harmonic Bio (Nasdaq: THRD), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. CEO Natalie Holles wird bei den folgenden Veranstaltungen an Gesprächen teilnehmen:
- Virtueller Immunologie- und Entzündungsgipfel von Stifel 2024 am 18. September 2024 um 9:00 Uhr ET
- Virtueller Gipfel zu chronischer Urtikaria von TD Cowen am 20. September 2024 um 15:00 Uhr ET
Das Unternehmen, das sich auf die Entwicklung innovativer Behandlungen für dermale, respiratorische und gastrointestinale Entzündungserkrankungen konzentriert, wird Live-Audio-Webcasts dieser Sitzungen auf seiner Website bereitstellen. Archivierte Aufzeichnungen sind nach den Veranstaltungen 90 Tage lang verfügbar.
- None.
- None.
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences:
- Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET
- TD Cowen Virtual Chronic Urticaria Summit on Friday, September 20, 2024, at 3:00 p.m. ET
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
What investor conferences will Third Harmonic Bio (THRD) participate in during September 2024?
Who will represent Third Harmonic Bio (THRD) at the September 2024 investor conferences?
What is the focus area of Third Harmonic Bio (THRD)?
How can investors access Third Harmonic Bio's (THRD) conference presentations in September 2024?
